According to the findings published in the New England Journal of Medicine, the weight loss drug vegovi has treated a serious form of liver disease in most patients in a major clinical test.

Steotic liver disease associated with metabolic dysfunction, also known as a non -closure fatty liver disease, affects more than 30 percent of adults in the United States, is a condition where excess fat is formed in liver, not due to excessive alcohol consumption, but often due to lifestyle factors such as obesity and chaythi syndrome. In addition, more than 7 percent of the disease is a more advanced form, known as steatohepatitis, or mash associated with metabolic dysfunction – which is caused by drinking.

According to doctors, both conditions occur when your body starts storing too much fat in the liver, causing swelling, scarring and even fibrosis. If left untreated, the condition may cause malignant liver failure and liver cancer.

About 63 percent reduced liver inflammation

The test funded by drug manufacturer Novo Nordisk included about 1,000 patients who had mash and were given a weekly 2.4-milegram dose of semaglutide, ingredient and vegovi, or a placebo for 72 weeks. According to the findings of the test, about 63 percent of patients with the Semaglutide group reduced liver inflammation, while 34.3 percent of people had a placebo compared to people.

Before the test begins, participants had moderate to a high level of scar tissue in the liver, known as stage 2 or 3 fibrosis – a pathological process where excessive scarring develops in tissues and organs, often caused by chronic inflammation or injury.

In addition, about 40 percent of the Semaglutide group saw an improvement in their fibrosis, while in the placebo group compared to 22.4 percent. Testing results add to the increasing list of conditions that are included in the GLP-1S-drug class, including ozmpic and vagovi of Novo Nordisk and Vagovi and Ellie Lily’s silence and zipbounds-which can behave in addition to diabetes and weight loss.

Vagovi has also been approved by food and drug administration to reduce the risk of heart disease in those with obesity. Many other drugs such as Jeepbounds have been approved for obstructive sleep apnea and can treat chronic kidney disease in patients with ozapic type 2 diabetes.

It is under investigation to find out if drugs are effective against Alzheimer’s and alcohol addiction.

What were the side effects?

According to scientists, even though the drug was well tolerated in the test, the most common side effects were gastrointestinal, including nausea, diarrhea, constipation and vomiting. The side effects for those who get out of the test were 2.6 percent for the Semglutide group and 3.3 percent for the placebo group.

Now get the latest news with health and braking news and top headlines worldwide.